


# Introduction



**119 mi covid19 cases, 2,6 mi deaths**






Administrative boundaries: © EuroGeographics © UN-FAO © Turkstat. The boundaries and names shown on this map do not imply official endorsement or acceptance by the European Union. Date of production: 25/02/2021

## SAGE extra-ordinary meeting, 15 March 2021

Dr Hanna Nohynek, SAGE Member, Chair Working Group on COVID-19 Vaccination

# WHO SAGE Policy development: steps and processes

- |   | <b>Status update</b>  |
|---|---|
| 1. <b>Values Framework</b> for the allocation and prioritization of COVID-19 vaccination: Principles, objectives and target groups of a COVID-19 vaccination programme  |  Endorsed by SAGE and published Sept 14 2020*  |
| 2. <b>Guidance on prioritization of target populations</b> under supply constrained situations: development of use case scenarios of limited vaccine under different epidemiological settings                                       |  Endorsed by SAGE at plenary meeting October 5-7°  |
| 3. <b>Policy recommendations on the use of COVID-19 vaccines</b> once authorized; under consideration of product-specific data and attributes, and with consideration of the regulatory status (emergency use or full registration) |  Timelines depends on registration by countries or Emergency Use Listing/ prequalification by WHO; two recommendation meetings held in January, one in February 2021 |

(\*available on: <https://www.who.int/immunization/policy/sage/en/>)

(° Approved by DG WHO, publication imminent)

# Interim recommendations already finalized



Interim recommendations for use of the Pfizer–  
BioNTech COVID-19 vaccine, BNT162b2, under  
Emergency Use Listing

Interim guidance  
8 January 2021

Interim recommendations for use of the Moderna  
mRNA-1273 vaccine against COVID-19

Interim guidance  
25 January 2021



Interim recommendations for use of the AZD1222  
(ChAdOx1-S [recombinant]) vaccine against COVID-  
19 developed by Oxford University and AstraZeneca

Interim guidance  
10 February 2021



# Agenda of SAGE today on 15 March 2021



12.05 - Update on recent developments including COVAX. K. O'BRIEN.

12.15 - Introduction and objective setting. H. NOHYNEK.

12.20 -Vaccine safety and efficacy data emerging on Janssen's Ad26.COVS.2.S COVID-19 vaccine clinical trials (phase 1-3 trial results). Risk management plans and other implementation considerations. COMPANY PRESENTATION 25 + 15 min

13.00 – Break

13.10 - Assessment of the critical evidence. SAGE COVID-19 WORKING GROUP 40 + 40 min AL. WILDER-SMITH, S.OMER, S.KOCHHAR, M.MARTI

14.30 - Presentation and discussion of the remaining draft recommendations. H.NOHYNEK 30 + 30 min

15.30 – End of meeting